Blog
RSS FeedPosted by Michael Wonder on 26 Apr 2021
Global sarcoma therapy now approved for Australian patients
23 April 2021 - Globally regarded soft tissue sarcoma therapy has been approved by the Therapeutic Goods Administration for Australian patients. ...
Posted by Michael Wonder on 18 Apr 2021
Cancer researcher David Thomas says more should be done attract big pharma
18 April 2021 - A Garvan Institute cancer researcher says the government needs to attract big pharmaceutical companies to Australia ...
Posted by Michael Wonder on 30 Mar 2021
Terminal cancer patients denied new treatments due to slow TGA approval
31 March 2021 - Desperate cancer patients are begging Australia’s drugs regulator to save lives by speeding up approvals and cutting ...
Posted by Michael Wonder on 02 Feb 2021
Precision medicine helping to change the prognosis of a rare subtype of bowel cancer
2 February 2021 - Australians with a specific type of bowel cancer are no longer subject to a ‘one-size fits ...
Posted by Michael Wonder on 08 Dec 2020
Telix granted TGA priority review for prostate cancer imaging
7 December 2020 - Telix announces today that the Company’s preliminary application to the TGA for TLX591-CDx was made at ...
Posted by Michael Wonder on 06 Nov 2020
New drug for gastro-intestinal stromal tumours to be launched in Australia, New Zealand and South East Asia following distribution agreement
5 November 2020 - Qinlock is already approved by the TGA and US FDA. ...
Posted by Michael Wonder on 06 Oct 2020
PixCell Medical announces regulatory approval from Australian TGA for HemoScreen point of care hematology analyser
5 October 2020 - PixCell Medical announced today that it has received regulatory approval from the Australian TGA for the ...
Posted by Michael Wonder on 14 Sep 2020
Revolutionary cancer medicine Vitrakvi shrinks tumours in days
14 September 2020 - Doctors are amazed by a new cancer medicine offering Australian kids a new lease on life, but ...
Posted by Michael Wonder on 02 Sep 2020
TGA announces it has approved Yescarta
2 September 2020 - Announcement in September of a decision made in February. ...
Posted by Michael Wonder on 13 Aug 2020
Seattle Genetics announces Tukysa (tucatinib) approved within months for all countries participating in FDA’s Project Orbis initiative
12 August 2020 - Australia joins U.S., Switzerland, Canada and Singapore in approval of Tukysa for the treatment of patients with ...
Posted by Michael Wonder on 29 Jul 2020
TGA approves new medicine for basal cell carcinoma
29 July 2020 - Cemiplimab (Libtayo) has been provisionally registered by the TGA. ...
Posted by Michael Wonder on 15 Jul 2020
Deciphera announces Australian Therapeutic Goods Administration’s approval of Qinlock (ripretinib) for the treatment of fourth-line gastro-intestinal stromal tumour
14 July 2020 - Qinlock is the first approved tyrosine kinase inhibitor designed specifically for GIST regardless of patients’ mutational status. ...
Posted by Michael Wonder on 04 Jun 2020
New small cell lung cancer drug accepted for TGA evaluation under Project Orbis
3 June 2020 - TGA has granted provisional designation for new drug lurbinectedin based on encouraging Phase 2 results and high ...
Posted by Michael Wonder on 25 May 2020
TGA approves Rozlytrek
25 May 2020 - Roche secures TGA approval for another cancer medicine. ...
Posted by Michael Wonder on 25 Nov 2019
Acalabrutinib receives TGA approval for CLL and SLL cancers
25 November 2019 - The Therapeutic Goods Administration has approved the use of acalabrutinib (Calquence) for the treatment of patients ...